Navigation Links
Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
Date:6/5/2011

EAST HANOVER, N.J., June 5, 2011 /PRNewswire/ -- Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking Gleevec® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on Sunday, June 5.

The results show that at five years 66% of patients taking Gleevec for three years remained free of cancer recurrence (primary endpoint) compared to 48% who had received Gleevec for only one year (p<0.0001). Moreover, 92% of patients taking Gleevec for three years were alive (secondary endpoint) compared to 82% who had received Gleevec for only one year (p=0.019) (1). Median patient follow-up was 54 months.

The 400-patient Phase III trial, conducted by the Scandinavian Sarcoma Group (SSG) and the Sarcoma Group of the Arbeitsgemeinschaft Internistische Onkologie (AIO), is the first prospective multicenter clinical trial to demonstrate a survival benefit of adjuvant Gleevec therapy for KIT+ GIST with extended three years of therapy relative to one year of therapy. The side effect profile in the clinical trial was consistent with that reported in previous studies with Gleevec.

"This study confirms the hypothesis that extending the duration of Gleevec treatment for patients following surgery improves recurrence-free survival. For the first time, an effect on overall survival was found," said Heikki Joensuu, M.D., Ph.D., Professor, Oncology, University of Helsinki and principal investigator of the study. "Results from this trial may positively impact clinical practice by helping physicians create the optimal treatment plan for patients with operable KIT+ GIST."

Gastrointestinal stromal tumors are a rare, life-threatening cancer of the gastrointestinal
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
2. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
3. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
4. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
5. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
6. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
7. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
8. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
9. Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
10. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
11. Final Approval of Novartis Gender Discrimination Settlement Slated for November 19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015  The quality function within the ... products meet quality standards at every stage of the ... quality leaders also have the challenge of balancing quality ... Those who don,t effectively balance these priorities risk funding ... marketplace failure and regulatory scrutiny. For the ...
(Date:3/27/2015)... SALT LAKE CITY , March 27, 2015 ... Richard J. Linder has been appointed to the Company,s ... vacancy created by the death in November 2014 of board ... of Rich Linder to our Board of Directors ... Kelvyn Cullimore, Jr. , chairman and president of Dynatronics.  "Rich ...
(Date:3/27/2015)... TEMPLE, Texas , March 27, 2015 The ... relocate in April to a 5,000-square-foot building at 1802 South ... a geographic area designated by the City of ... Baylor Scott & White and the Central Texas Veterans Health ... office and laboratory space to early stage biotechnology and life ...
Breaking Medicine Technology:New Medical Device Quality Study Finds Regulatory Environment is Boosting Quality Spending, Especially for Large Companies 2Dynatronics Announces Appointment of Richard J. Linder to Board of Directors 2Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2
... Calif., Oct. 3, 2011 VIVUS, Inc. (NASDAQ: ... presented at Obesity 2011:  The 29 th Annual ... Orlando, Florida. The presentations highlighted the long-term beneficial effects ... weight loss.  Specifically, Qnexa patients had significant improvement in ...
... KALONA, Iowa, Sept. 30, 2011 CIVCO Medical ... Andres Ramirez as Sales Director of Advanced Robotics ... international sales efforts for the Protura Robotic Patient ... System. (Logo:   http://photos.prnewswire.com/prnh/20110419/AQ85801LOGO ) ...
Cached Medicine Technology:Two-year Treatment With Qnexa Has Benefits Beyond Weight Loss 2Two-year Treatment With Qnexa Has Benefits Beyond Weight Loss 3Two-year Treatment With Qnexa Has Benefits Beyond Weight Loss 4Two-year Treatment With Qnexa Has Benefits Beyond Weight Loss 5Two-year Treatment With Qnexa Has Benefits Beyond Weight Loss 6CIVCO Appoints Andres Ramirez Sales Director of Advanced Robotics and Workflow Solutions 2
(Date:3/30/2015)... National Nutrition Month is an ... habits and commit to nutritious decisions that will affect their ... a recent study from the U.S. Department of Agriculture (USDA), ... Making healthy snack choices needs to be an essential piece ... on the go. , Each day, millions of Americans turn ...
(Date:3/29/2015)... 30, 2015 Over 50 million women ... to undiagnosed autoimmune, thyroid, or hormone disorders. , Dr. ... personally treated hundreds of patients dealing with these conditions, ... the treatment options for their ailments. Her new book, ... women living with fatigue, brain fog, and sleepless nights. ...
(Date:3/29/2015)... Adults who are comparing the different ... the web can now use the QuotesPros.com website for ... now be explored while researching the automated database now ... differences between what a term policy provides and what ... some men and women. Insurers typically provide base pricing ...
(Date:3/29/2015)... (PRWEB) March 29, 2015 The ... clinical trials and research, manage data results and ... their clients reach regulation standards. Contract research organizations ... medical device manufacturing sectors. Industry operators provide clients ... to late-stage clinical research for Food and Drug ...
(Date:3/29/2015)... California (PRWEB) March 29, 2015 ... a new transition from Pixel Film Studios, entitled TranSports. ... transitions made exclusively for Final Cut Pro X,” said ... our users the tools needed to effortlessly transition using ... introduces TranSports, a new and uniquely styled transition pack ...
Breaking Medicine News(10 mins):Health News:Benefits of Healthy Snacking — HealthyYOU Vending Machines Offer 21 Healthy Snack Selections for People on the Go 2Health News:Benefits of Healthy Snacking — HealthyYOU Vending Machines Offer 21 Healthy Snack Selections for People on the Go 3Health News:How to Turn Mid-life into the Good Life 2Health News:Permanent Life Insurance Quotes Now Offered Through Web Search System at Insurer Website Online 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2
... ... at conference, ATLANTA, Feb. 26 Pamela Bishop, head ... featured presenter at the,2008 Run Walk Ride Fundraising Conference (RWRFC) ... at 4:00 p.m. EST,providing an overview of ING,s successful cause-marketing ...
... Alimera Sciences has entered into a,second exclusive ... management -- specifically the reduction of reactive,oxygen species ... The agreement gives Alimera the exclusive option ... as triphenylmethanes, as a potential,treatment for ocular disorders ...
... FRANCISCO, Feb. 26 VIA Pharmaceuticals,Inc. (Nasdaq: VIAP ... for the treatment of cardiovascular disease, announced today that,James ... VIA,will present a company update at the Susquehanna Second ... at 1:30 p.m. ET at the W,Hotel in New ...
... high blood sugar condition linked to high mortality ... effort is needed to deal with the effects of ... Heart Association scientific statement released Monday. , The statement ... also known as hyperglycemia, in people hospitalized with acute ...
... Quality Cardiology Center Seeks End to Soaring Health Costs, ... Hospital,one of the nation,s leading cardiology treatment centers, announced ... for one of the most common types of,open heart ... Wichita,Eagle published this week. "After carefully studying our costs ...
... Stock Exchange Symbol: CYT ... http://www.cryocath.com ... leader in cryotherapy products to treat cardiac,arrhythmias, today announced that Chief ... 4, 2008. Effective April 7,2008, Ginette Gagne will take over the ...
Cached Medicine News:Health News:ING Run for Something Better to be Featured at 2008 Run Walk Ride Fundraising Conference 2Health News:ING Run for Something Better to be Featured at 2008 Run Walk Ride Fundraising Conference 3Health News:ING Run for Something Better to be Featured at 2008 Run Walk Ride Fundraising Conference 4Health News:Alimera Sciences Signs Second Agreement With Emory University for Potential Treatments Using New Class of Antioxidants 2Health News:Alimera Sciences Signs Second Agreement With Emory University for Potential Treatments Using New Class of Antioxidants 3Health News:National Effort Needed to Address Hyperglycemia in Heart Patients 2Health News:CryoCath Appoints New Chief Financial Officer 2
Angled, 7.5 mm tying platforms.,Titanium, 111 mm long, 6 mm tying platforms....
Gills Colibri forceps, very fine pointed tips....
Castroviejo tying forceps, tying platforms, straight, 0.3 mm teeth....
Microsurgical straight forceps made of titanium has straight shafts with smooth working surface. TCI working parts 6 mm from tips with round handle, diam. 6 mm, overall length 116 mm....
Medicine Products: